Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Obtain key information regarding the latest in pharmaceutical research from Informa Pharma Intelligence.
You’ve already tuned into Pharma R&D Annual Review 2018, the free, music-themed whitepaper from Citeline’s Pharmaprojects (which you can still access below). Now, get even more free market data and insights with your download of Pharma R&D Annual Review 2018 Supplement: New Active Substances Launched During 2017.
Examine the most successful new active substances (NASs) that hit the market for the first time in 2017. Find out:
Pharmaprojects’ analysts have compiled a compelling view of R&D, past, present, and future. Download your free report today, and discover:
A total pipeline overview, including an overview by phase
Which companies have the most drugs currently in the pipeline
The top therapeutic focus in R&D pipelines
A view of the types of drugs in the pipeline – are biologics the wave of the future?
The top mechanisms of action and targets of investigation
Outlook for the future: what’s in store?
Medtech Insight
By Ashley Yeo 11 Dec 2019
The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings.
In Vivo
By Ashley Yeo 11 Dec 2019
For providers and medtech manufacturers alike, the decade ahead will be a time of coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market entry criterion, but companies will have to adapt to evolving health care delivery models. The stakes are implausibly high. Will they be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?
Generics Bulletin
By Aidan Fry 11 Dec 2019
For the first time, a working group within the International Council for Harmonization has started work on a regulatory topic specifically tailored to the global generics and biosimilars industry.
HBW Insight
By Malcolm Spicer 11 Dec 2019
Senate's Over-the-Counter Monograph Safety, Innovation, and Reform Act goes next for consideration by House, which has had a bill by the same title on its floor for a vote since it was passed by Energy and Commerce Committee in late June.
HBW Insight
By Ryan Nelson 11 Dec 2019
Farah Ahmed, president and CEO of the Fragrance Creators Association, discusses the trade group’s expansion in recent years beyond immediate regulatory and legislative concerns to a platform for robust member collaboration in the name of positively impacting the world.
Medtech Insight
By Amanda Maxwell 11 Dec 2019
Only just over a month ago there were fears that the implementation of the EU Medical Device Regulation was going to be hampered by a lack of expert panel applicants. Now it seems there is no shortage. The news raises lots of questions about when and how the structure will now work.
In Vivo
10 Dec 2019
Your key to refining your market access strategy with essential patient market access mini-mag and infographic from the experts at In Vivo.
Pink Sheet
By Brenda Sandburg 06 Dec 2019
Rising Pharmaceuticals agrees to pay $3.1m, admits to conspiring to fix prices for hypertension drug, and enters into deferred prosecution agreement. Pfizer asks court to be removed from complaint by state AGs.
In Vivo
By Ian Schofield 06 Dec 2019
Three Brexit deadlines have come and gone, and the UK is still a member of the European Union. It will remain so until it agrees a withdrawal deal or leaves without one at the end of January 2020. Alternatively, it could secure yet another extension to the Article 50 period beyond January 31. Or it could decide not to leave at all.
HBW Insight
By Malcolm Spicer 06 Dec 2019
Recent statement that FDA has not found evidence supporting CBD as GRAS for use in human or animal food potentially points to NDI notifications as the only option manufacturers, marketers and other businesses will have to convince agency about safety for CBD and other hemp-derived substances used in dietary supplements.
HBW Insight
By Tom Gallen 06 Dec 2019
GSK has launched Flunase in Japan following the switch of fluticasone propionate. JSMI’s Toshi Tominaga gives his assessment of the product’s prospects as an OTC drug.
Generics Bulletin
By Aidan Fry 06 Dec 2019
US niche generics player Teligent intends to use its expertise in topical and injectable drugs manufacturing to push into the North American ophthalmics sector.
Medtech Insight
06 Dec 2019
Swedish cancer diagnostics firm Biovica International announces a new R&D director; Convergent Dental, a dental equipment company, and XACT Robotics, a robotics system developer, pick sales veeps; and more.
Topic Medtech
Medtech Insight
By Amanda Maxwell 06 Dec 2019
The two-year delay to Eudamed was a Commission decision. Now the competent authorities are fighting back and the issue is to be discussed at the level of the Council of the European Union on December 9 to avoid “heavily burdensome administrative transitional solutions.”
Scrip
By Leah Samuel 06 Dec 2019
Early adopters of artificial intelligence are discovering how best to use it. Some of them are sharing lessons they have learned.
In Vivo
12 Dec 2019
Medtech Insight
12 Dec 2019
Scrip
12 Dec 2019
In Vivo
12 Dec 2019
Pink Sheet
12 Dec 2019
Pink Sheet
12 Dec 2019
Medtech Insight
12 Dec 2019
Scrip
12 Dec 2019
Scrip
11 Dec 2019
Pink Sheet
11 Dec 2019
Pink Sheet
11 Dec 2019
Medtech Insight
11 Dec 2019
Scrip
11 Dec 2019
Scrip
11 Dec 2019
Scrip
11 Dec 2019
Approximately 400,000 investigators in over 170 countries, all with clinical trial experience, all at your fingertips. Support your trial success and inform your principal investigator (PI) and site selection activities with Sitetrove, now on a sleek, modern interface for simpler, faster and more efficient searching.
Key benefits:
Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.
Key benefits:
The industry’s most trusted drug development database, Citeline's Pharmaprojects has been covering pharma R&D across global markets for 35+ years. With 68,000+ drug profiles including 15,000 drugs in active development, it’s the go-to resource for preclinical, clinical, and pipeline coverage, and lifecycle management tracking.
Key benefits:
Request a live demo
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
How can we help you?
Our team is always happy to hear from you. Please call us at:
Pharma Report Store
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now:
